III期-话题@MedSci

#III期#

681篇内容 | 2785人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594527, encodeId=ff1c159452e04, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Janssen启动了Crohn''s药物Tremfya的PhII / III期计划, objectType=article, longId=144189, objectId=f0e314418910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0e314418910, replyNumber=0, likeNumber=68, createdTime=2018-07-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0e314418910, moduleTitle=Janssen启动了Crohn''s药物Tremfya的PhII / III期计划, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0e314418910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594526, encodeId=eef2159452693, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=【Best of ASCO 2018 China】胃肠肿瘤专场精彩回顾（2）—— S-1联合多西他赛对比S-1单药用于III期胃癌根治性手术后辅助治疗的随机对照, objectType=article, longId=142919, objectId=373b142919f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=373b142919f8, replyNumber=0, likeNumber=32, createdTime=2018-07-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=373b142919f8, moduleTitle=【Best of ASCO 2018 China】胃肠肿瘤专场精彩回顾（2）—— S-1联合多西他赛对比S-1单药用于III期胃癌根治性手术后辅助治疗的随机对照, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=373b142919f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594525, encodeId=5c301594525f9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=【Best of ASCO 2018 China】胃肠肿瘤专场精彩回顾（1）——AspECT 阿司匹林与埃索美拉唑预防Barrett’s食管化生的III期对照研, objectType=article, longId=142918, objectId=4d8014291804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8014291804, replyNumber=0, likeNumber=36, createdTime=2018-07-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8014291804, moduleTitle=【Best of ASCO 2018 China】胃肠肿瘤专场精彩回顾（1）——AspECT 阿司匹林与埃索美拉唑预防Barrett’s食管化生的III期对照研, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8014291804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594524, encodeId=689a159452442, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, objectType=article, longId=142862, objectId=f2bb142862d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2bb142862d6, replyNumber=0, likeNumber=82, createdTime=2018-07-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2bb142862d6, moduleTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2bb142862d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594523, encodeId=65b015945234c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, objectType=article, longId=141928, objectId=2c18141928fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c18141928fb, replyNumber=0, likeNumber=79, createdTime=2018-06-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c18141928fb, moduleTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c18141928fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594522, encodeId=7361159452242, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期, objectType=article, longId=141716, objectId=f67b141e169c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f67b141e169c, replyNumber=0, likeNumber=0, createdTime=2018-06-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f67b141e169c, moduleTitle=辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f67b141e169c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594521, encodeId=126415945211d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=试验神药Napabucasin肝癌控制率达100%？III期却不容乐观, objectType=article, longId=140285, objectId=fd01140285bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd01140285bb, replyNumber=0, likeNumber=61, createdTime=2018-06-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd01140285bb, moduleTitle=试验神药Napabucasin肝癌控制率达100%？III期却不容乐观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd01140285bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594520, encodeId=ab03159452084, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究, objectType=article, longId=139735, objectId=3b5d139e35b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b5d139e35b5, replyNumber=0, likeNumber=71, createdTime=2018-06-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b5d139e35b5, moduleTitle=ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b5d139e35b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594519, encodeId=710415945194d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Journal of Clinical Gastroenterology：鳞状细胞癌抗原血清测定可以作为Barrett食管和食管癌的生物标记物：III期研究, objectType=article, longId=139693, objectId=10331396935d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10331396935d, replyNumber=0, likeNumber=36, createdTime=2018-06-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10331396935d, moduleTitle=Journal of Clinical Gastroenterology：鳞状细胞癌抗原血清测定可以作为Barrett食管和食管癌的生物标记物：III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10331396935d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594518, encodeId=d1561594518f7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JAMA：II-III期结肠癌患者术后CT及癌胚抗原筛查频率不影响患者生存期, objectType=article, longId=139025, objectId=24b2139025b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24b2139025b0, replyNumber=0, likeNumber=117, createdTime=2018-05-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24b2139025b0, moduleTitle=JAMA：II-III期结肠癌患者术后CT及癌胚抗原筛查频率不影响患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24b2139025b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594517, encodeId=584f159451ec7, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=曲马多治疗术后疼痛的III期临床数据, objectType=article, longId=138881, objectId=706b138881e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=706b138881e9, replyNumber=0, likeNumber=64, createdTime=2018-05-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=706b138881e9, moduleTitle=曲马多治疗术后疼痛的III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=706b138881e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594516, encodeId=910915945161b, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, objectType=article, longId=137196, objectId=7db713e1967a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7db713e1967a, replyNumber=0, likeNumber=81, createdTime=2018-05-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7db713e1967a, moduleTitle=Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7db713e1967a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594515, encodeId=3906159451543, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, objectType=article, longId=136871, objectId=94111368e1b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94111368e1b3, replyNumber=0, likeNumber=0, createdTime=2018-05-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94111368e1b3, moduleTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94111368e1b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594514, encodeId=5021159451471, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=tivozanib治疗索拉非尼治疗后晚期肾细胞癌患者的疗效：III期交叉研究, objectType=article, longId=136869, objectId=073213686943, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=073213686943, replyNumber=0, likeNumber=0, createdTime=2018-05-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=073213686943, moduleTitle=tivozanib治疗索拉非尼治疗后晚期肾细胞癌患者的疗效：III期交叉研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=073213686943)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594513, encodeId=523015945134e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Vertex在III期临床试验中测试CF三联疗法, objectType=article, longId=136761, objectId=2419136e61db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2419136e61db, replyNumber=0, likeNumber=53, createdTime=2018-04-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2419136e61db, moduleTitle=Vertex在III期临床试验中测试CF三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2419136e61db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594512, encodeId=6e15159451225, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=安罗替尼III期研究ALTER0303数据写入《2018版CSCO肺癌指南》, objectType=article, longId=136178, objectId=a6311361e8bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6311361e8bb, replyNumber=0, likeNumber=43, createdTime=2018-04-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6311361e8bb, moduleTitle=安罗替尼III期研究ALTER0303数据写入《2018版CSCO肺癌指南》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6311361e8bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594511, encodeId=096e159451126, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM：Keytruda辅助治疗可显著提高III期黑色素瘤患者生存率, objectType=article, longId=135501, objectId=edf51355017d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf51355017d, replyNumber=0, likeNumber=54, createdTime=2018-04-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf51355017d, moduleTitle=NEJM：Keytruda辅助治疗可显著提高III期黑色素瘤患者生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf51355017d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594510, encodeId=a46215945108d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, objectType=article, longId=135459, objectId=662a13545945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662a13545945, replyNumber=0, likeNumber=31, createdTime=2018-04-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662a13545945, moduleTitle=PLOS ONE：天花疫苗MVA的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662a13545945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594509, encodeId=a31815945096a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Tafamidis符合甲状腺素心肌病III期试验的主要目标, objectType=article, longId=134232, objectId=617013423247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=617013423247, replyNumber=0, likeNumber=63, createdTime=2018-04-05, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=617013423247, moduleTitle=Tafamidis符合甲状腺素心肌病III期试验的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=617013423247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594508, encodeId=7bbe15945085e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=FDA扩大Adcetris适应症至III期或IV期经典霍奇金淋巴瘤, objectType=article, longId=133451, objectId=835d13345119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=835d13345119, replyNumber=0, likeNumber=76, createdTime=2018-03-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=835d13345119, moduleTitle=FDA扩大Adcetris适应症至III期或IV期经典霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=835d13345119)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Janssen启动了Crohn''s药物Tremfya的PhII / III期计划

2018-07-13

智智灵药 (审核中...)

前往app查看评论内容

#III期#

【Best of ASCO 2018 China】胃肠肿瘤专场精彩回顾（2）—— S-1联合多西他赛对比S-1单药用于III期胃癌根治性手术后辅助治疗的随机对照

2018-07-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

【Best of ASCO 2018 China】胃肠肿瘤专场精彩回顾（1）——AspECT 阿司匹林与埃索美拉唑预防Barrett’s食管化生的III期对照研

2018-07-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据

2018-07-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

安进公司宣布生物仿制药ABP 710的III期临床研究结果

2018-06-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期

2018-06-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

试验神药Napabucasin肝癌控制率达100%？III期却不容乐观

2018-06-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究

2018-06-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Journal of Clinical Gastroenterology：鳞状细胞癌抗原血清测定可以作为Barrett食管和食管癌的生物标记物：III期研究

2018-06-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JAMA：II-III期结肠癌患者术后CT及癌胚抗原筛查频率不影响患者生存期

2018-05-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

曲马多治疗术后疼痛的III期临床数据

2018-05-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Nat Med：“靶向化疗”成为可能—卡铂用于治疗BRCA1/2突变及BRCAness表型三阴性乳腺癌的III期TNT研究

2018-05-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活

2018-05-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

tivozanib治疗索拉非尼治疗后晚期肾细胞癌患者的疗效：III期交叉研究

2018-05-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Vertex在III期临床试验中测试CF三联疗法

2018-04-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

安罗替尼III期研究ALTER0303数据写入《2018版CSCO肺癌指南》

2018-04-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM：Keytruda辅助治疗可显著提高III期黑色素瘤患者生存率

2018-04-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

PLOS ONE：天花疫苗MVA的III期临床试验结果

2018-04-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Tafamidis符合甲状腺素心肌病III期试验的主要目标

2018-04-05

智智灵药 (审核中...)

前往app查看评论内容

#III期#

FDA扩大Adcetris适应症至III期或IV期经典霍奇金淋巴瘤

2018-03-27

科室
- - 订阅+
  - 更多科室
工具
服务